Stay updated with breaking news from Late Breaking Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer’s diseaseAdditional late-breaking presentations from the CLARITY AD study explore...
New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.
Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , a... | May 10, 2023
Late-breaking Phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly...